MARKET

TRVI

TRVI

Trevi Therapeutics
NASDAQ
14.50
+0.45
+3.20%
After Hours: 14.75 +0.25 +1.73% 19:24 05/08 EDT
OPEN
14.46
PREV CLOSE
14.05
HIGH
15.35
LOW
14.39
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
16.12
52 WEEK LOW
5.38
MARKET CAP
1.86B
P/E (TTM)
-44.8361
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)
TipRanks · 1d ago
TREVI THERAPEUTICS INC <TRVI.O>: STIFEL RAISES TARGET PRICE TO $30 FROM $18
Reuters · 2d ago
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson
Reuters · 2d ago
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
TipRanks · 2d ago
Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
TipRanks · 3d ago
Analysts Are Bullish on Top Healthcare Stocks: Trevi Therapeutics (TRVI), EyePoint Pharmaceuticals (EYPT)
TipRanks · 3d ago
Trevi Therapeutics Charts Cash-Rich Path Through Key Trials
TipRanks · 3d ago
Trevi Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
More
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Webull offers Trevi Therapeutics Inc stock information, including NASDAQ: TRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVI stock methods without spending real money on the virtual paper trading platform.